Skip to content
Dosage GuideResearch Reference

Retatrutide Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Retatrutide. All information is for educational purposes only.

Quick Answer

Retatrutide is currently an investigational drug; as such, definitive human dosage guidelines are not yet established. Phase 2 clinical trials evaluated subcutaneous doses ranging from 1 mg to 12 mg weekly. Weight loss efficacy appears dose-dependent. Consult a qualified medical professional for guidance.

→ Retatrutide Benefits→ Retatrutide Side Effects→ Full Retatrutide Profile
Table of Contents

Standard Dosage Range

Research dosing range: 1–12 mg per week (subcutaneous)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Obesity / Weight Loss

1-12 mg1× weekly
Duration

24-72 weeks (trial dependent)

Administered subcutaneously. Phase 2 trials used escalating doses. Optimal dose balancing efficacy and tolerability is being evaluated in Phase 3.

Type 2 Diabetes Management

1-12 mg1× weekly
Duration

24-72 weeks (trial dependent)

Subcutaneous injection. Monitored for HbA1c reduction and glycemic control. Dosing considerations similar to obesity protocols.

NASH / NAFLD (investigational)

5-12 mg1× weekly
Duration

48-72 weeks (projected)

Currently under investigation for non-alcoholic steatohepatitis. Higher doses may be required. Liver enzyme monitoring is critical.

Timing & Frequency

Administered once weekly, typically any time of day. Consistent timing is recommended to maintain stable plasma concentrations given its long half-life (~6 days). Consider administering in the morning to mitigate potential nighttime side effects.

Cycle Guidance

Clinical trials have ranged from 24 to 72 weeks. The long-term safety and efficacy of retatrutide are still being evaluated. As an investigational medication, cycling protocols are not yet established.

Reconstitution Reference

Quick reference for reconstituting Retatrutide. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeVariable, dependent on source (research grade typically in mg)
BAC Water VolumeDependent on vial size and desired concentration. Consult supplier documentation.
Concentration & DrawDependent on reconstitution volume. Calculate to achieve desired dose per injection volume.
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at recommended temperature per manufacturer.
StabilityDependent on formulation and storage conditions. Refer to supplier documentation for stability data.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical starting dose of retatrutide?
Clinical trials have initiated dosing at 1mg weekly, escalating gradually to mitigate side effects. However, retatrutide is an investigational drug, and specific dosing should be determined by a qualified medical professional only.
How is retatrutide administered?
Retatrutide is administered via subcutaneous injection, typically once weekly.
What is the half-life of retatrutide?
The estimated half-life of retatrutide is approximately 6 days, supporting once-weekly administration.
Can retatrutide be taken orally?
No, retatrutide is currently only available as a subcutaneous injection.

Last updated: 2026-02-26